AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11708574 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/day
Number of subjects: 89
Study 11708574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 8780541 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation
Number of subjects: 0
Study 1882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g b.i.d.
Number of subjects: 52
Study 1882907 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 1 g q.i.d.
Number of subjects: 52
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 2 micrograms kg‐1
Number of subjects: 171
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: alcuronium 0.03 mg kg‐1
Number of subjects: 171
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 1 microgram kg‐1
Number of subjects: 171
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: tubocurarine 0.06 mg kg‐1
Number of subjects: 171
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium 0.01 mg kg‐1
Number of subjects: 171
Study 6882613 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 171
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 171
Study 6882613 — intervention group
Group type: EXPERIMENTAL
Intervention: tubocurarine
Number of subjects: 171
Study 31812110 — intervention group
Group type: EXPERIMENTAL
Intervention: s-adenosyl methionine (MSI-195)
Number of subjects: 0
Study 31812110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30688979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (systolic blood pressure goal < 120 mm Hg; n = 4678)
Number of subjects: 9361
Study 30688979 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (systolic blood pressure goal < 140 mm Hg; n = 4683)
Number of subjects: 9361
Study 30688979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 9361
Study 30688979 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 9361
Study 28617764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of 0.2 mL of mother's colostrum every 4 hours for 7 days
Number of subjects: 64
Study 28617764 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 64
Study 28617764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum
Number of subjects: 64
Study 27703563 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oscillometric blood pressure device (Dinamap Procare 100)
Number of subjects: 200
Study 27703563 — intervention group
Group type: COMPARATOR
Intervention: Manual mercury sphygmomanometer
Number of subjects: 200
Study 24422892 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by at least six cycles of intravenous platinum-based chemotherapy
Number of subjects: 230
Study 24422892 — intervention group
Group type: COMPARATOR
Intervention: At least six cycles of intravenous platinum-based chemotherapy
Number of subjects: 230
Study 26557330 — intervention group
Group type: EXPERIMENTAL
Intervention: LiSN & Learn auditory training program
Number of subjects: 10
Study 26557330 — intervention group
Group type: COMPARATOR
Intervention: Earobics auditory training program
Number of subjects: 10
Study 19269520 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy
Number of subjects: 1156
Study 19269520 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential resection margin negative
Number of subjects: 1156
Study 19269520 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential resection margin positive
Number of subjects: 1156
Study 19269520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plane of surgery achieved - mesorectal
Number of subjects: 1156
Study 19269520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plane of surgery achieved - intramesorectal
Number of subjects: 1156
Study 19269520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plane of surgery achieved - muscularis propria
Number of subjects: 1156
Study 17898947 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) therapy for detoxification, removing stasis, and nourishing yin, in addition to prednisone, for 6 months.
Number of subjects: 170
Study 17898947 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (WM group) treated with prednisone for 6 months.
Number of subjects: 170
Study 17898947 — intervention group
Group type: COMPARATOR
Intervention: Follow-up study in IM group (25 patients) and WM group (16 patients).
Number of subjects: 170
Study 15180973 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 8
Study 15180973 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 12195686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg orally prior to thrombolysis and 12 hours later
Number of subjects: 99
Study 12195686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 9579293 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa + apomorphine (1 mg/h)
Number of subjects: 10
Study 9579293 — intervention group
Group type: COMPARATOR
Intervention: levodopa + saline (placebo)
Number of subjects: 10
Study 7898706 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A botulinum toxin
Number of subjects: 9
Study 7898706 — intervention group
Group type: EXPERIMENTAL
Intervention: Type F botulinum toxin
Number of subjects: 9
Study 2347694 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based program with one education and two fitness sessions per week for 14 weeks; included individual counseling, small group education, aerobic activity, and snack components.
Number of subjects: 94
Study 2347694 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 94
Study 434745 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-0 Dexon 'S' polyglycolic acid sutures
Number of subjects: 30
Study 434745 — intervention group
Group type: COMPARATOR
Intervention: 8-0 Vicryl polyglactin sutures
Number of subjects: 30
Study 31141115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinematic Rendering (CR)
Number of subjects: 40
Study 31141115 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 40
Study 27685757 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with liquid-based cytology (LBC) triage for HPV positives
Number of subjects: 25152
Study 27685757 — intervention group
Group type: COMPARATOR
Intervention: Control arm - Baseline liquid-based cytology (LBC) with ASCUS results triaged with HPV testing
Number of subjects: 25152
Study 27685757 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with LBC triage for HPV positives
Number of subjects: 25152
Study 27685757 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with LBC triage for HPV positives in women ≥35 years
Number of subjects: 25152
Study 27685757 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing in women 25-29
Number of subjects: 25152
Study 25971394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (core temperature 34.5-35°C)
Number of subjects: 60
Study 25971394 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (core temperature 36.5-37°C)
Number of subjects: 60
Study 23926587 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage lateral window sinus lift with simultaneous implant placement
Number of subjects: 60
Study 23926587 — intervention group
Group type: COMPARATOR
Intervention: 2-stage procedure with implant placement delayed by 4 months
Number of subjects: 60
Study 21307655 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY‐TT
Number of subjects: 606
Study 21307655 — intervention group
Group type: COMPARATOR
Intervention: Hib‐TT
Number of subjects: 606
Study 19037018 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtraction MR images
Number of subjects: 40
Study 19037018 — intervention group
Group type: COMPARATOR
Intervention: Native MR images
Number of subjects: 40
Study 17338822 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist care manager (GCM) intervention
Number of subjects: 45
Study 17338822 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 45
Study 15472162 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty as a selection criterion
Number of subjects: 0
Study 15472162 — intervention group
Group type: COMPARATOR
Intervention: Chronological age as a selection criterion
Number of subjects: 0
Study 11218582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization
Number of subjects: 59
Study 11218582 — intervention group
Group type: COMPARATOR
Intervention: Ureaplasma urealyticum negative
Number of subjects: 59
Study 11218582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization in infants with birth weight of 1,000 g or less
Number of subjects: 59
Study 11218582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization in infants with patent ductus arteriosus
Number of subjects: 59
Study 9396895 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of intravaginal misoprostol
Number of subjects: 75
Study 9396895 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of pharmacy-prepared intravaginal prostaglandin E2 gel
Number of subjects: 75
Study 8187445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospidine (500 mg every 3-5 days intravenously, then monthly)
Number of subjects: 27
Study 8187445 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (30 mg/week intravenously in hospital, then orally 7.5-15 mg/week)
Number of subjects: 27
Study 8187445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospidine
Number of subjects: 27
Study 8187445 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 27
Study 8187445 — intervention group
Group type: COMPARATOR
Intervention: Prospidine and Methotrexate
Number of subjects: 27
Study 3492164 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 173
Study 3492164 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 173
Study 31603201 — intervention group
Group type: EXPERIMENTAL
Intervention: EBOV GP vaccine with Matrix‐M adjuvant (2 doses)
Number of subjects: 230
Study 31603201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 29924240 — intervention group
Group type: EXPERIMENTAL
Intervention: U-MDT regimen (six doses of MB-MDT: rifampicin, dapsone, and clofazimine)
Number of subjects: 753
Study 29924240 — intervention group
Group type: COMPARATOR
Intervention: R-MDT regimen (six doses for PB: rifampicin and dapsone; 12 doses for MB: rifampicin, dapsone, and clofazimine)
Number of subjects: 753
Study 29924240 — intervention group
Group type: COMPARATOR
Intervention: R-MDT regimen
Number of subjects: 753
Study 29924240 — intervention group
Group type: EXPERIMENTAL
Intervention: U-MDT regimen
Number of subjects: 753
Study 27367750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus maintenance arm
Number of subjects: 10
Study 27367750 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 10
Study 25557189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychosocial stress task
Number of subjects: 45
Study 25557189 — intervention group
Group type: COMPARATOR
Intervention: Non-stress control condition
Number of subjects: 45
Study 21541732 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g/day CLA mixture (36.9% cis-9, trans-11 and 37.9% trans-10, cis-12)
Number of subjects: 29
Study 21541732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.4 g olive oil/day)
Number of subjects: 29
Study 19282299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg(‐1)
Number of subjects: 44
Study 19282299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 44
Study 19282299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg(‐1)
Number of subjects: 44
Study 19282299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg kg(‐1)
Number of subjects: 44
Study 19282299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (all doses)
Number of subjects: 44
Study 18055735 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception
Number of subjects: 6389
Study 14675064 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of zoledronic acid (ZOL)
Number of subjects: 20
Study 14675064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12003652 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron tablets (65 mg of iron and 0.25 mg of folic acid) given for 10 weeks
Number of subjects: 1113
Study 12003652 — intervention group
Group type: COMPARATOR
Intervention: No iron tablets (control group)
Number of subjects: 1113
Study 12003652 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention for untreated girls (control group)
Number of subjects: 1113
Study 12003652 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention for untreated boys (control group)
Number of subjects: 1113
Study 9689339 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg o.d.)
Number of subjects: 38
Study 9689339 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg o.d.)
Number of subjects: 38
Study 9689339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7980837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassava-salt suspension (CSS)
Number of subjects: 132
Study 7980837 — intervention group
Group type: COMPARATOR
Intervention: WHO recommended ORS
Number of subjects: 132
Study 2510271 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 600 micrograms nocte
Number of subjects: 208
Study 2510271 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 300 mg nocte
Number of subjects: 208
Study 1157717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of heparin
Number of subjects: 225
Study 1157717 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparinate (conventional high doses)
Number of subjects: 225
Study 1157717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 225
Study 31067718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (500 μg IV injections)
Number of subjects: 26
Study 31067718 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 26
Study 29861395 — intervention group
Group type: EXPERIMENTAL
Intervention: CBDCA with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15 of each 21-day cycle)
Number of subjects: 250
Study 29861395 — intervention group
Group type: COMPARATOR
Intervention: DOC (60 mg/m2 intravenous [I.V.] on day 1)
Number of subjects: 250
Study 27185685 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position with IV ephedrine
Number of subjects: 56
Study 27185685 — intervention group
Group type: COMPARATOR
Intervention: Supine position with IV ephedrine
Number of subjects: 56
Study 23238880 — intervention group
Group type: COMPARATOR
Intervention: 125-Hz sinusoidal vibration at 0 ms(‐2) rms
Number of subjects: 0
Study 23238880 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-Hz sinusoidal vibration at 22 ms(‐2) rms
Number of subjects: 0
Study 23238880 — intervention group
Group type: EXPERIMENTAL
Intervention: 125-Hz sinusoidal vibration at 88 ms(‐2) rms
Number of subjects: 0
Study 23238880 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-N force with vibration (7.5 or 15 min)
Number of subjects: 0
Study 23238880 — intervention group
Group type: COMPARATOR
Intervention: 2-N force without vibration
Number of subjects: 0
Study 22157880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 204
Study 22157880 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 204
Study 22157880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise training
Number of subjects: 204
Study 22157880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 22157880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 204
Study 20301021 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) - sirolimus-eluting stents (SES)
Number of subjects: 23
Study 20301021 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 23
Study 20301021 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 23
Study 20301021 — intervention group
Group type: COMPARATOR
Intervention: Combined DES and BMS
Number of subjects: 23
Study 17243915 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (folic acid, B6, and B12) for 8 weeks
Number of subjects: 230
Study 17243915 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 230
Study 16344029 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 20
Study 16344029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 12587414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HAD)
Number of subjects: 75
Study 12587414 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest of HAD
Number of subjects: 75
Study 9889429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine sustained-release tablets
Number of subjects: 13
Study 7698384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) after controlled ovarian hyperstimulation (COH)
Number of subjects: 46
Study 7698384 — intervention group
Group type: COMPARATOR
Intervention: Timed intercourse (TI) after controlled ovarian hyperstimulation (COH)
Number of subjects: 46
Study 2664571 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg i.v./i.m. b.i.d., starting the day before the surgery for 8 days)
Number of subjects: 102
Study 2664571 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5000 IU s.c. b.i.d., starting on the day of surgery, for 4 days)
Number of subjects: 102
Study 357231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 10
Study 31860601 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 88
Study 31730474 — intervention group
Group type: EXPERIMENTAL
Intervention: Web survey
Number of subjects: 0
Study 31730474 — intervention group
Group type: COMPARATOR
Intervention: Paper survey
Number of subjects: 0
Study 31730474 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure enclosure
Number of subjects: 0
Study 31730474 — intervention group
Group type: COMPARATOR
Intervention: No brochure enclosure
Number of subjects: 0
Study 27484763 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghuang Shengbai Granule (SSG) for 14 days starting on the first day of chemotherapy
Number of subjects: 330
Study 25807090 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg daily for 14 days, then 200 mg daily for 14 days)
Number of subjects: 31
Study 25807090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25807090 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 31
Study 21344260 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g intravenously 30 min before surgery
Number of subjects: 76
Study 21344260 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously 30 min before surgery
Number of subjects: 76
Study 18945577 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachiocephalic arteriovenous fistula (BCAVF)
Number of subjects: 100
Study 18945577 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachiobasilic arteriovenous fistula (BBAVF)
Number of subjects: 100
Study 18945577 — intervention group
Group type: COMPARATOR
Intervention: Control group (BCAVF)
Number of subjects: 100
Study 18945577 — intervention group
Group type: COMPARATOR
Intervention: Control group (BBAVF)
Number of subjects: 100
Study 17196358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling
Number of subjects: 1244
Study 17196358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print
Number of subjects: 1244
Study 17196358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling and print
Number of subjects: 1244
Study 17196358 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1244
Study 14689227 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (CM) at 4 ml/s followed by 40 ml of saline chaser at 4 ml/s
Number of subjects: 42
Study 14689227 — intervention group
Group type: COMPARATOR
Intervention: 140 ml of contrast material (CM) at 4 ml/s
Number of subjects: 42
Study 14689227 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of CM with saline chaser
Number of subjects: 42
Study 14689227 — intervention group
Group type: COMPARATOR
Intervention: 140 ml of CM
Number of subjects: 42
Study 11870505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin suspension (5 mg in 1 ml, 150 mg m(‐2), max 300 mg, max fluid 60 ml)
Number of subjects: 30
Study 11870505 — intervention group
Group type: COMPARATOR
Intervention: Usual cisplatin solution (150 mg m(‐2) dissolved in 500 ml saline)
Number of subjects: 30
Study 11870505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received intravenous infusion of sodium thiosulphate (9 g m(‐2))
Number of subjects: 30
Study 11870505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin suspension
Number of subjects: 30
Study 9649985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 42
Study 9649985 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 42
Study 8031162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU tablets administered at a dose of 200 mg/day for 6 months
Number of subjects: 200
Study 8031162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU tablets administered at a dose of 200 mg/day for 12 months
Number of subjects: 200